Challenges and perspective of drug repurposing strategies in early phase clinical trials

Despite significant investments in the development of new agents only 5% of cancer drugs entering Phase I clinical trials are ultimately approved for routine clinical cancer care. Drug repurposing strategies using novel combinations of previously tested anticancer agents could reduce the cost and im...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Shumei, Moulder, Stacy L., Ueno, Naoto T., Wheler, Jennifer J., Meric-Bernstam, Funda, Kurzrock, Razelle, Janku, Filip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506360/
https://www.ncbi.nlm.nih.gov/pubmed/26244164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506360/
https://www.ncbi.nlm.nih.gov/pubmed/26244164

Ejemplares similares